The groundbreaking rise of Viagra has firmly established as a benchmark of pharmaceutical success, yet its legacy within the broader market now triggers questions about potential yields . Alternative versions are diminishing exclusivity , causing worries that investing in companies heavily reliant to Viagra's once-dominant position could be a probl